Both in the case of trastuzumab and tucatinib, we observed that the sensitivity of our model was reduced if compared to the response of the human HER2+++ breast cancer cell line BT-474 (halved for trastuzumab and three times lower for tucatinib). Here, ERBB2 is linked to breast carcinoma.